ALUNBRIG, generically known as brigatinib, is a prescription medication used in the treatment of non-small cell lung cancer (NSCLC) that has a specific genetic marker known as anaplastic lymphoma kinase (ALK) positive. As a targeted therapy, ALUNBRIG works by inhibiting the activity of the ALK protein, which can contribute to the growth and spread of cancer cells. It is typically prescribed for patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor. Available in tablet form, ALUNBRIG is taken orally and its use is associated with a range of potential side effects, which can vary in severity. It represents a significant advancement in the personalized treatment approach for lung cancer, offering hope for improved outcomes in a subset of patients with this challenging disease.